NASDAQ:HOWL Werewolf Therapeutics (HOWL) Stock Price, News & Analysis $0.91 +0.04 (+4.81%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$0.90 -0.02 (-1.91%) As of 04/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Werewolf Therapeutics Stock (NASDAQ:HOWL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Werewolf Therapeutics alerts:Sign Up Key Stats Today's Range$0.86▼$0.9350-Day Range$0.87▼$1.5252-Week Range$0.86▼$6.89Volume219,371 shsAverage Volume385,493 shsMarket Capitalization$40.90 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company OverviewWerewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.Read More… Remove Ads Werewolf Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreHOWL MarketRank™: Werewolf Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 699th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingWerewolf Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageWerewolf Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Werewolf Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Werewolf Therapeutics are expected to decrease in the coming year, from ($1.56) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Werewolf Therapeutics is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Werewolf Therapeutics is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWerewolf Therapeutics has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Werewolf Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.04% of the float of Werewolf Therapeutics has been sold short.Short Interest Ratio / Days to CoverWerewolf Therapeutics has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Werewolf Therapeutics has recently increased by 1.52%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldWerewolf Therapeutics does not currently pay a dividend.Dividend GrowthWerewolf Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.04% of the float of Werewolf Therapeutics has been sold short.Short Interest Ratio / Days to CoverWerewolf Therapeutics has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Werewolf Therapeutics has recently increased by 1.52%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Werewolf Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Werewolf Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Werewolf Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.10% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.84% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Werewolf Therapeutics' insider trading history. Receive HOWL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HOWL Stock News HeadlinesWerewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 31 at 8:00 AM | globenewswire.comWerewolf Therapeutics (HOWL) Gets a Buy from Bank of America SecuritiesMarch 28, 2025 | markets.businessinsider.com“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.April 3, 2025 | Weiss Ratings (Ad)Analysts Are Bullish on Top Healthcare Stocks: Werewolf Therapeutics (HOWL), Exelixis (EXEL)March 13, 2025 | markets.businessinsider.comWerewolf Therapeutics Faces Geopolitical Risks Amid Changing Trade Policies with ChinaMarch 12, 2025 | tipranks.comWerewolf Therapeutics Reports 2024 Financial Results and ProgressMarch 12, 2025 | tipranks.comWerewolf Therapeutics reports Q4 EPS (46c), consensus (31c)March 11, 2025 | markets.businessinsider.comWerewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 11, 2025 | globenewswire.comSee More Headlines HOWL Stock Analysis - Frequently Asked Questions How have HOWL shares performed this year? Werewolf Therapeutics' stock was trading at $1.48 at the beginning of 2025. Since then, HOWL shares have decreased by 38.4% and is now trading at $0.9124. View the best growth stocks for 2025 here. How were Werewolf Therapeutics' earnings last quarter? Werewolf Therapeutics, Inc. (NASDAQ:HOWL) announced its quarterly earnings results on Tuesday, March, 11th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.03. Werewolf Therapeutics had a negative trailing twelve-month return on equity of 58.83% and a negative net margin of 578.80%. When did Werewolf Therapeutics IPO? Werewolf Therapeutics (HOWL) raised $101 million in an IPO on Friday, April 30th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. How do I buy shares of Werewolf Therapeutics? Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Werewolf Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Werewolf Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL). Company Calendar Last Earnings3/11/2025Today4/03/2025Next Earnings (Estimated)5/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HOWL CIK1785530 Webwerewolftx.com Phone617-952-0555FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$15.00 Low Stock Price Target$4.00 Potential Upside/Downside+886.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,370,000.00 Net Margins-578.80% Pretax Margin-1,834.55% Return on Equity-58.83% Return on Assets-38.45% Debt Debt-to-Equity Ratio0.29 Current Ratio10.10 Quick Ratio10.10 Sales & Book Value Annual Sales$1.89 million Price / Sales21.70 Cash FlowN/A Price / Cash FlowN/A Book Value$3.08 per share Price / Book0.30Miscellaneous Outstanding Shares44,827,000Free Float35,160,000Market Cap$40.90 million OptionableOptionable Beta0.37 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:HOWL) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.